Eplerenone Versus Spironolactone as Treatment of Ascites Due to Liver Cirrhosis; a Study of Efficacy and Side Effects

• Status: Withdrawn
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: Male

Summary

This study compares Spironolactone, a non-selective aldosterone antagonist, with Eplerenone, a selective aldosterone antagonist, regarding efficacy and hormonal side effects when treating male cirrhotic patients with uncomplicated ascites over a 6 month period. The investigators hypothesis is that Eplerenone is as effective as Spironolactone as treatment of ascites with less side effects such as painful gynecomastia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Emma Nilsson
• Collaborators: Göteborg University; Karolinska University Hospital; Region Örebro County; University Hospital, Linkoeping; University Hospital, Umeå; Uppsala University Hospital
• Treatments: Eplerenone; Spironolactone

Criteria

Inclusion Criteria:

Male Ascites Cirrhosis

-

Exclusion Criteria:

Prior treatment with aldosterone antagonist Uncontrolled heart disease or diabetes Current malignancy Current medication interacting with aldosterone antagonists